Q-Line Biotech (NSE:QLINE) Current Deferred Revenue: ₹0 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:QLINE Q-Line Biotech Ltd NSE:QLINE
14 GF Score
Price ₹530.85
! 2 Warning Signs
View Full Analysis

What is Q-Line Biotech Current Deferred Revenue?

Q-Line Biotech NSE:QLINE -0.18% 14 Current Deferred Revenue is ₹0 Mil as of Mar. 2025. GuruFocus rates NSE:QLINE with a GF Score™ of 14/100. The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Q-Line Biotech's current deferred revenue for the quarter that ended in Mar. 2025 was ₹0 Mil.

Q-Line Biotech Current Deferred Revenue Related Terms

Q-Line Biotech Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Q-Line Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Q-Line Biotech Current Deferred Revenue Chart

Q-Line Biotech Annual Data
Trend Mar23 Mar24 Mar25
Current Deferred Revenue
0.00 0.00 0.00

Q-Line Biotech Semi-Annual Data
Mar23 Mar24 Mar25
Current Deferred Revenue 0.00 0.00 0.00
NSE:QLINE
14GF Score
Q-Line Biotech Ltd NSE:QLINE
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
Q-Line Biotech (NSE:QLINE) has a Current Deferred Revenue of ₹0 Mil as of Mar. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Current Deferred Revenue too high?
Q-Line Biotech's current Current Deferred Revenue is ₹0 Mil. Overall, Q-Line Biotech has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Current Deferred Revenue compare to ABT and SYK?
Q-Line Biotech's Current Deferred Revenue of ₹0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Medical Devices & Instruments company?
A good Current Deferred Revenue depends on the Medical Devices & Instruments industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Current Deferred Revenue of ₹0 Mil. The current Current Deferred Revenue is ₹0 Mil. Q-Line Biotech's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Current Deferred Revenue is ₹0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q-Line Biotech Business Description

Address Kanpur Road Adjacent Transport Nagar Metro Station, 298-281, Transport Nagar, Lucknow, UP, IND, 226012
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
14GF Score

Get the complete analysis for NSE:QLINE

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹530.85
Price